This module focuses on two recent trials that investigated the use of SGLT-2 inhibitors in patients with heart failure: EMPEROR-Reduced (which looked at empagliflozin) and DAPA-HF (which studied dapagliflozin). The module sets out the background to the trials and their design and assesses how their results might be applied to clinical practice.
By the end of this module, you will be able to:
✓ Explain the rationale for investigating the efficacy and safety of treatment with SGLT-2 inhibitors in patients with heart failure and a reduced ejection fraction, with or without diabetes
✓ Identify the key features of the DAPA-HF and EMPEROR-Reduced clinical trials
✓ Apply the results of the DAPA-HF and EMPEROR-Reduced trials to the management of typical patients with diabetes
This module includes self-marked assessments, such as knowledge checks and/or case studies, as well as a marked final assessment, which you can attempt up to five times. To complete the module, you must review all chapters, pass the final assessment (80% pass mark), and fill in our feedback form.